Use

When treatment of rheumatic diseases with infliximab or its biosimilar fails, a physician may need to consider adjusting dose or dosing intervals, switching to a different TNF blocker, or switching to a different drug agent (e.g., a non-TNF blocker). This assay specifically measures serum infliximab and infliximab‑dyyb (Inflectra) levels. Clinical studies suggest target infliximab trough concentrations of 2–8 mcg/mL or 2–10 mcg/mL in rheumatoid arthritis. Equivalence studies support applying infliximab clinical guidance to its biosimilars.